CymaBay Therapeutics, Inc. (CBAY)

NASDAQ: CBAY · IEX Real-Time Price · USD
32.28
+0.05 (0.16%)
At close: Feb 26, 2024, 4:00 PM
32.23
-0.05 (-0.15%)
After-hours: Feb 26, 2024, 7:54 PM EST
0.16%
Market Cap 3.70B
Revenue (ttm) 31.02M
Net Income (ttm) -90.10M
Shares Out 114.79M
EPS (ttm) -0.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,262,076
Open 32.23
Previous Close 32.23
Day's Range 32.21 - 32.31
52-Week Range 7.26 - 32.31
Beta 0.28
Analysts Hold
Price Target 27.33 (-15.33%)
Earnings Date Mar 14, 2024

About CBAY

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of selade... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Sujal A. Shah
Employees 63
Stock Exchange NASDAQ
Ticker Symbol CBAY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for CBAY stock is "Hold." The 12-month stock price forecast is $27.33, which is a decrease of -15.33% from the latest price.

Price Target
$27.33
(-15.33% downside)
Analyst Consensus: Hold
Stock Forecasts

News

The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis

-  Seladelpar demonstrated normalization of liver biomarkers and significant reductions across three measures of patient-reported itch vs. placebo -  NEWARK, Calif.

5 days ago - PRNewsWire

CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWARK, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic dise...

6 days ago - GlobeNewsWire

CYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAY

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of CymaBay Therapeu...

Other symbols: GILD
10 days ago - Business Wire

Why Gilead Sciences Is Buying CymaBay Therapeutics for $4.3 Billion

Shares of CymaBay Therapeutics (CBAY) soared to an all-time high Monday after Gilead Sciences (GILD) announced it's buying the developer of medicine for liver and other chronic diseases for $4.3 billi...

Other symbols: GILD
14 days ago - Investopedia

Shareholder Alert: Ademi LLP investigates whether CymaBay Therapeutics, Inc. has obtained a Fair Price in its transaction with Gilead

MILWAUKEE , Feb. 12, 2024 /PRNewswire/ -- Ademi LLP is investigating CymaBay (Nasdaq: CBAY)  for possible breaches of fiduciary duty and other violations of law in its transaction with Gilead. Click h...

14 days ago - PRNewsWire

CymaBay Therapeutics Shares Hit All-Time High on Gilead Deal

CymaBay Therapeutics shares jumped nearly 25% and hit a new record high in early trading after the clinical-stage biopharmaceutical company agreed to be acquired by Gilead Sciences for $4.3 billion.

Other symbols: GILD
14 days ago - WSJ

CBAY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CymaBay Therapeutics, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) to Gilead Sciences, Inc. for $32.50 per share i...

14 days ago - Business Wire

Gilead to buy CymaBay Therapeutics for $4.3 billion

CymaBay Therapeutics Inc (NASDAQ: CBAY) opened more than 25% up this morning after Gilead Sciences Inc (NASDAQ: GILD) said it will buy the biopharmaceutical company for $4.3 billion. Details of Gilead...

Other symbols: GILD
14 days ago - Invezz

CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis

-  FDA has granted Priority Review with a target PDUFA date of August 14 - NEWARK, Calif. , Feb. 12, 2024 /PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused...

14 days ago - PRNewsWire

Drugmaker Gilead to acquire CymaBay for $4.3 bln

Gilead Sciences on Monday said it will acquire CymaBay Therapeutics for $4.3 billion, to expand its portfolio of liver disease drugs.

Other symbols: GILD
14 days ago - Reuters

Gilead strikes deal to acquire CymaBay for $4.3 billion

Gilead Sciences Inc. GILD, -0.18% said Monday it has reached a deal to acquire CymaBay Therapeutics Inc. CBAY, +2.92% for $32.50 per share in cash, a 27% premium to CymaBay's closing price Friday, for...

Other symbols: GILD
14 days ago - Market Watch

Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics

FOSTER CITY, Calif. & NEWARK, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will...

Other symbols: GILD
14 days ago - Business Wire

CymaBay Therapeutics to Participate in Upcoming Investment Conferences

NEWARK, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic disea...

26 days ago - GlobeNewsWire

New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay's Seladelpar

-- First clinical trial in PBC to show coordinate reductions of IL-31, bile acids and pruritus -- NEWARK, Calif. , Jan. 3, 2024 /PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmace...

7 weeks ago - PRNewsWire

CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024

NEWARK, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic disea...

7 weeks ago - GlobeNewsWire

CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis

- NDA is supported by data evaluating seladelpar efficacy and safety in over 500 patients -  - Seladelpar is the first New Drug Application from CymaBay in its ongoing mission to help people living wi...

2 months ago - PRNewsWire

Best Small-Cap Stocks to Buy for 2024 and Beyond

Wall Street's best small-cap stocks to buy include pharma, biotech and specialty retail names.

2 months ago - Kiplinger

CymaBay Announces an Oral Presentation of Seladelpar Phase 3 Pivotal Results in Primary Biliary Cholangitis at the Late Breaker Session of the Liver Meeting®

61.7% of patients on seladelpar 10 mg achieved the primary composite endpoint vs. 20.0% of patients on placebo (p

3 months ago - PRNewsWire

CymaBay Reports Third Quarter and Nine Months Ended September 30, 2023 Financial Results and Provides Corporate Update

Announced top-line results from RESPONSE Phase 3 study in PBC where seladelpar met the primary and two key secondary endpoints with high statistical significance.

3 months ago - GlobeNewsWire

CymaBay Therapeutics to Present at Upcoming Investment Conferences

NEWARK, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic disea...

4 months ago - GlobeNewsWire

CymaBay Announces Publication of Two-year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis

NEWARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic disea...

4 months ago - GlobeNewsWire

CymaBay Therapeutics to Report Third Quarter of 2023 Financial Results on Tuesday, November 7, 2023

NEWARK, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic disea...

4 months ago - GlobeNewsWire

CymaBay Presents Results on the Potential of Seladelpar in Treatment of Patients with Primary Biliary Cholangitis at ACG 2023

Cholestatic pruritus expert leads plenary discussion of correlated decreases in serum IL-31 levels and pruritus among patients with PBC treated with seladelpar

4 months ago - GlobeNewsWire

Seladelpar Granted Revised Breakthrough Therapy Designation for the Treatment of Primary Biliary Cholangitis Including Pruritus in Patients Without Cirrhosis or With Compensated Cirrhosis

NEWARK, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic disea...

4 months ago - GlobeNewsWire

CymaBay's RESPONSE Phase 3 Data Evaluating Seladelpar for Primary Biliary Cholangitis to be Featured in an Oral Late-Breaking Presentation at The Liver Meeting® 2023

Results from the RESPONSE registrational study to be highlighted in oral presentation on Monday, November 13th Fifth oral late-breaking presentation of seladelpar results at The Liver Meeting® NEWARK,...

4 months ago - GlobeNewsWire